ReviewThe Korean journal of internal medicine2021
Blood pressure control in patients with chronic kidney disease.
Review in The Korean journal of internal medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- Saudi Clinical Practice Guidelines for management of diabetic kidney disease in adults.Saudi medical journal · 2025Guideline
- Kidney-Related Screening Indicator Trends in Korea: 2010-2024 (eGFR, 2012-2024) and 2025-2028 Forecasts Using National Health Insurance Service Health Screening Data.Medicina (Kaunas, Lithuania) · 2026Article
- Knowledge domains and emerging trends in aldosterone and kidney disease prognosis: a bibliometric analysis.International urology and nephrology · 2026Review
- Review
- BP and Kidney Disease Progression in Advanced CKD: Findings from the Chronic Renal Insufficiency Cohort and KoreaN Cohort Study for Outcome in Patients with CKD Studies.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Identifying the optimal blood pressure target among Korean hemodialysis patients: current evidence and future directions.Kidney research and clinical practice · 2025Article
- Alterations in gut-kidney axis indicators and TMAO-related biomarkers in elderly patients with hypertensive nephropathy.Frontiers in medicine · 2025Article
- Blood pressure control in diabetic kidney disease: a post-hoc analysis of the FANTASTIC trial.Clinical hypertension · 2024Article
- Prognostic factors affecting long-term outcomes in patients with concurrent IgA nephropathy and membranous nephropathy.Heliyon · 2024Article
- Article
- Hypothetical intervention of targeted systolic blood pressure control of < 120 mmHg on renal prognosis for persons with stage 3-4 chronic kidney disease: an application of parametric g-formula using health checkup data in Japan.Clinical and experimental nephrology · 2023Article
- Development of a Korean-specific cardiovascular risk model in a cohort at high-risk of hypertension.The Korean journal of internal medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Uncontrolled blood pressure (BP) in patients with chronic kidney disease (CKD) can lead to serious adverse outcomes. To prevent the occurrence of cardiovascular events (CVEs), and end-stage kidney disease, achieving an optimal BP level is important. Recently, there has been a paradigm shift in the management of BP largely as a result of the Systolic Blood Pressure Intervention Trial (SPRINT), which showed a reduction in CVEs by lowering systolic BP to 120 mmHg. A lower systolic blood pressure (SBP) target has been accepted by the Kidney Disease: Improving Global Outcomes (KDIGO) 2021 guidelines. However, whether intensive control of SBP targeting < 120 mmHg is also effective in patients with CKD is controversial. Notably, this lower target SBP is associated with a higher risk of adverse kidney outcomes. Unfortunately, there have been no randomized controlled trials on this issue involving only patients with CKD, particularly those with advanced CKD. In this review, we discuss the optimal control of BP in patients with CKD in terms of reduction in death and CVEs as well as attenuation of CKD progression based on the evidence-based literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.